Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Therapeutic Drug Monitoring
34%
Chemotherapy
18%
Malignant Neoplasm
18%
Alectinib
13%
Non Small Cell Lung Cancer
13%
Vincristine
12%
Anticancer Drug
12%
Neoplasm
12%
Olaparib
11%
Childhood Cancer
11%
Sunitinib
10%
Pharmacodynamics
10%
Pemetrexed
9%
Gallium 68
9%
CYP3A4
9%
Cisplatin
8%
Biological Marker
8%
Anticarcinogen
8%
Progression Free Survival
8%
Carboplatin
8%
Adverse Event
8%
Phosphotransferase Inhibitor
8%
Overall Survival
8%
Pharmacokinetic Modeling
7%
Breast Cancer
7%
Visceral Leishmaniasis
7%
Imatinib
7%
Paclitaxel
7%
Abiraterone
7%
Randomized Controlled Trial
7%
Mouse Model
6%
Acute Lymphoblastic Leukemia
6%
Diseases
5%
Drug-Drug Interaction
5%
Tolerability
5%
Cmin
5%
Aprepitant
5%
Ritonavir
5%
Osimertinib
5%
Allopurinol
5%
Docetaxel
5%
Transgenic Mouse
5%
Thymocyte Antibody
5%
Miltefosine
5%
Ovary Cancer
5%
Paromomycin
5%
Pembrolizumab
5%
Methotrexate
5%
Clinical Study
5%
Doxorubicin
5%
Creatinine
5%
Castration Resistant Prostate Cancer
5%
Keyphrases
Pharmacokinetics
43%
Therapeutic Drug Monitoring
21%
Population Pharmacokinetics
11%
Confidence Interval
9%
Pediatric Patients
9%
Treatment Outcome
9%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
8%
Pemetrexed
7%
Human Plasma
7%
Olaparib
6%
Chemotherapy Toxicity
6%
Clinical Practice
6%
Oncology
6%
Pediatric Oncology
6%
Plasma Concentration
6%
Non-small Cell Lung Cancer Patients
6%
Clinical Pharmacology
5%
Aprepitant
5%
Neonate
5%
Human Serum
5%
Ritonavir
5%
Precision Dosing
5%
Kinase Inhibitor
5%
Antithymocyte Globulin
5%
Overall Survival
5%
Cisplatin
5%
High Risk
5%
Drug Use
5%
Dose-limiting Toxicity
5%